When should a fasting lipid panel be ordered in adults and how should abnormal results be managed?

When to Order a Lipid Panel in Adults

For adults not on lipid-lowering therapy, obtain a lipid panel at diabetes diagnosis or initial evaluation, and every 5 years thereafter if under age 40; for those over 40, screening should occur at least once and more frequently based on cardiovascular risk factors. 1

Initial Screening Recommendations

General Adult Population

• Baseline screening at age 20 years (fasting or non-fasting) is advised to establish cardiovascular risk 2
• Targeted screening for men >40 years and women >50 years (or post-menopausal) is especially important 2
• Young adults (18-39 years) should be screened when any of the following are present: 2
  • Family history of premature ASCVD (men <55 years, women <65 years)
  • Diabetes, hypertension, obesity, or smoking
  • A parent with total cholesterol ≥240 mg/dL or known dyslipidemia

Diabetes-Specific Screening

• Obtain lipid profile at time of diabetes diagnosis, at initial medical evaluation, and at least every 5 years thereafter in patients <40 years of age 1
• In younger patients with longer disease duration (such as youth-onset type 1 diabetes), more frequent lipid profiles may be reasonable 1

Fasting vs. Non-Fasting: A Practical Approach

Non-fasting lipid panels are acceptable for most screening and risk assessment purposes. 1, 3 The maximal mean changes at 1-6 hours after habitual meals are not clinically significant: +0.3 mmol/L (26 mg/dL) for triglycerides, -0.2 mmol/L (8 mg/dL) for total cholesterol, and -0.2 mmol/L (8 mg/dL) for LDL cholesterol 3. Non-fasting and fasting concentrations vary similarly over time and are comparable in predicting cardiovascular disease 3.

However, fasting is preferred in specific situations: 2, 4, 5

• If non-fasting triglycerides ≥400 mg/dL, obtain a repeat fasting lipid panel 2
• Family history of premature ASCVD or genetic hyperlipidemia (to aid identification of familial lipid disorders) 1
• Suspected metabolic syndrome requiring clarification for lifestyle counseling 5
• Suspected hypertriglyceridemic pancreatitis 5

A 2024 meta-analysis of 244,665 participants concluded that fasting is preferred as a conservative model to reduce variability and increase consistency in metabolic status 6, though this conflicts with European and some U.S. guidelines that accept non-fasting samples 3.

Monitoring on Lipid-Lowering Therapy

Timing of Repeat Testing

Obtain a lipid profile 4-12 weeks after statin initiation or dose adjustment, then every 3-12 months (or annually) thereafter to monitor response and medication adherence 1, 2. Low-risk patients with optimal lipid profiles may be rechecked every 2 years 2.

Frequency Based on Risk

• High-risk individuals: annually 2
• Lower-risk adults: every 1-2 years 2
• Adults <40 years with low-risk lipid values (LDL-C <100 mg/dL, HDL-C >50 mg/dL, triglycerides <150 mg/dL): lipid assessments may be repeated every 2 years 1

---

Management of Abnormal Lipid Results

Risk Stratification First

Before initiating therapy, calculate 10-year ASCVD risk using the Pooled Cohort Equations (U.S.) or SCORE2 (Europe) for adults 40-75 years 2. This determines treatment intensity.

Very High-Risk Categories (Most Aggressive Therapy)

• Documented clinical ASCVD or unequivocal imaging evidence 2
• Diabetes with target-organ damage, ≥3 major risk factors, or type 1 diabetes >20 years duration 2
• Chronic kidney disease with eGFR <30 mL/min/1.73 m² 2
• History of multiple major ASCVD events 2
• Familial hypercholesterolemia with ASCVD or another major risk factor 2

High-Risk Categories

• 10-year ASCVD risk ≥20% 2
• Diabetes (age 40-75) without additional high-risk features 2
• LDL-C ≥190 mg/dL (severe primary hypercholesterolemia) 2

Intermediate-Risk

• 10-year ASCVD risk 7.5%-19.9% 2

Risk-Enhancing Factors (Upgrade Treatment When Present)

Family history of premature ASCVD, triglycerides ≥175 mg/dL, high-sensitivity CRP ≥2.0 mg/L, lipoprotein(a) ≥50 mg/dL (or 125 nmol/L), apolipoprotein B ≥130 mg/dL, CKD with eGFR 30-60 mL/min/1.73 m², metabolic syndrome, chronic inflammatory disorders (rheumatoid arthritis, psoriasis, HIV), history of preeclampsia or premature menopause (<40 years), ankle-brachial index <0.9 2

Coronary Artery Calcium (CAC) Scoring

CAC scoring is reasonable for intermediate-risk (7.5%-19.9%) or selected borderline-risk (5%-<7.5%) patients when treatment decisions are uncertain 2:

• CAC = 0: consider deferring statin except in smokers, diabetics, or strong family history 2
• CAC 1-99 (especially age ≥55 years): favors statin initiation 2
• CAC ≥100 or ≥75th percentile: statin therapy is indicated 2

Do not perform CAC scoring when statin therapy is already indicated by risk assessment 2

LDL-C Treatment Targets

Very High-Risk Patients

Aim for LDL-C <70 mg/dL (1.8 mmol/L) or ≥50% reduction if baseline 70-135 mg/dL 2; European guidelines further recommend <55 mg/dL (1.4 mmol/L) 1, 2

For acute coronary syndrome: initiate high-intensity statin immediately, often combined with ezetimibe 2

High-Risk Patients

Aim for LDL-C <100 mg/dL (2.6 mmol/L) or ≥50% reduction if baseline 100-200 mg/dL 2

Diabetes-Specific Targets

• Age 40-75 years: start moderate-intensity statin without risk calculation 1, 2
• Age ≥50 years or multiple risk factors: use high-intensity statin to achieve ≥50% LDL-C reduction 1, 2
• All ages with established CVD: high-intensity statin therapy 1, 2

Pharmacologic Management Algorithm

Step 1: Lifestyle Modification (All Patients)

Reduce saturated fat, trans fat, and dietary cholesterol; increase omega-3 fatty acids, viscous fiber (oats, legumes, citrus), and plant sterols/stanols; promote weight loss, regular physical activity, and optimal glycemic control in diabetics 1, 2

Step 2: Statin Intensity Selection

High-Intensity Statins (≥50% LDL-C reduction): 1, 2

• Atorvastatin 40-80 mg or rosuvastatin 20-40 mg
• Indicated for:
  • All ages with diabetes and ASCVD 1
  • Diabetes age 40-75 at higher cardiovascular risk (one or more ASCVD risk factors) 1
  • LDL-C ≥190 mg/dL 1, 2
  • Very high-risk patients 2

Moderate-Intensity Statins (30-49% reduction): 1, 2

• Atorvastatin 10-20 mg, rosuvastatin 5-10 mg, simvastatin 20-40 mg, pravastatin 40-80 mg
• Indicated for:
  • Diabetes age 40-75 without ASCVD 1
  • Diabetes age 20-39 with additional ASCVD risk factors (may be reasonable) 1
  • Adults >75 years (individualized discussion) 1

Step 3: Add Non-Statin Therapy When Needed

Ezetimibe: 1, 2

• Add when very high-risk patients on maximally tolerated statin have LDL-C ≥70 mg/dL
• Add when severe hypercholesterolemia (LDL-C ≥190 mg/dL) remains ≥100 mg/dL on statin
• Provides additional 15-20% LDL-C reduction
• For acute coronary syndrome: combine with high-intensity statin immediately 2

PCSK9 Inhibitors: 1, 2

• Consider for very high-risk patients with LDL-C ≥70 mg/dL despite statin + ezetimibe
• Consider for severe hypercholesterolemia with LDL-C ≥100 mg/dL on statin + ezetimibe plus multiple ASCVD risk factors
• Long-term safety beyond 3 years remains uncertain and cost-effectiveness is a concern 2

Triglyceride Management

Elevated Triglycerides (≥150 mg/dL)

Intensify lifestyle therapy and optimize glycemic control 1, 2

Severe Hypertriglyceridemia (≥500 mg/dL)

Evaluate secondary causes and consider pharmacologic therapy to reduce pancreatitis risk 2

Pharmacologic Options

• Fibrates: first-line for low HDL-C and elevated triglycerides; shown to reduce CVD events 1, 2
• Niacin: most effective HDL-C raiser but may increase blood glucose; modest dosing (750-2000 mg/day) recommended 2
• Icosapent ethyl (not mixtures of EPA and DHA) has shown benefit 2

Special Populations

Chronic Kidney Disease

• Adults ≥50 years with eGFR <60 mL/min/1.73 m²: treat with statin or statin + ezetimibe 2
• Adults 18-49 years with CKD: initiate statin if 10-year coronary death/MI risk ≥10% 2
• Do not start statins in dialysis patients, but continue if already prescribed at dialysis initiation 2
• Avoid high-intensity statins when eGFR <60 mL/min/1.73 m² due to polypharmacy concerns 2

Older Adults (>75 Years)

• Continue statin therapy in established ASCVD 1
• For primary prevention, initiate moderate-intensity statin after discussion of potential benefits and risks 1

Pregnancy

Statin therapy is contraindicated in pregnancy 1

Monitoring Treatment Response

Assess Adherence and Response

• Calculate achieved percentage LDL-C reduction versus expected based on statin intensity 1, 2
• High-intensity statin generally results in ≥50% LDL-C reduction from untreated baseline 1
• Moderate-intensity statin generally results in 30% to <50% LDL-C reduction 1

Address Inadequate Response

If LDL-C levels are not responding despite medication adherence: 1

• Reinforce adherence to intensive lifestyle changes
• Exclude secondary causes of hyperlipidemia (hypothyroidism, nephrotic syndrome, certain medications)
• Attempt to find a dose or alternative statin that is tolerable if side effects occur
• There is evidence for benefit from even extremely low, less than daily statin doses 1

Identify and Address Barriers

Identify barriers to medication adherence (such as cost and side effects) and address them proactively 1, 2

Common Pitfalls to Avoid

• Do not rely solely on LDL-C levels without calculating 10-year ASCVD risk in primary prevention 2
• Do not overlook risk-enhancing factors that could upgrade treatment intensity 2
• Do not use low-intensity statins when moderate or high intensity is warranted 2
• Do not delay combination therapy (statin + ezetimibe) in very high-risk patients, especially after acute coronary syndrome 2
• Do not fail to reassess lipid levels after initiating or adjusting therapy 2
• Do not ignore medication-adherence barriers; address cost and side-effect concerns proactively 2
• Do not omit evaluation for secondary causes of dyslipidemia 2